These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. Mehra S; Sahay S; Maji SK Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581 [TBL] [Abstract][Full Text] [Related]
8. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease. van Rooijen BD; Claessens MM; Subramaniam V Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294 [TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related]
10. Identification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p. Redeker V; Pemberton S; Bienvenut W; Bousset L; Melki R J Biol Chem; 2012 Sep; 287(39):32630-9. PubMed ID: 22843682 [TBL] [Abstract][Full Text] [Related]
11. Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell Models. Xin W; Emadi S; Williams S; Liu Q; Schulz P; He P; Alam NB; Wu J; Sierks MR Biomolecules; 2015 Jul; 5(3):1634-51. PubMed ID: 26287258 [TBL] [Abstract][Full Text] [Related]
14. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919 [TBL] [Abstract][Full Text] [Related]
15. Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau. Bhasne K; Sebastian S; Jain N; Mukhopadhyay S J Mol Biol; 2018 Aug; 430(16):2508-2520. PubMed ID: 29704492 [TBL] [Abstract][Full Text] [Related]
16. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. Alam P; Bousset L; Melki R; Otzen DE J Neurochem; 2019 Sep; 150(5):522-534. PubMed ID: 31254394 [TBL] [Abstract][Full Text] [Related]
17. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Conway KA; Harper JD; Lansbury PT Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204 [TBL] [Abstract][Full Text] [Related]
18. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. Cascella R; Bigi A; Cremades N; Cecchi C Cell Mol Life Sci; 2022 Mar; 79(3):174. PubMed ID: 35244787 [TBL] [Abstract][Full Text] [Related]
19. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491 [TBL] [Abstract][Full Text] [Related]